ID
45976
Beschrijving
Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Acute Kidney Injury https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000894 The goal of this study was to identify genetic variants associated with risk for acute kidney injury (AKI) in patients being treated with vancomycin and genetic variants associated with variability in vancomycin pharmacokinetics. AKI is a common adverse drug event and known complication of vancomycin therapy. Known risk factors fail to accurately predict renal toxicity. Our hypothesis, that genetic variants modify the risk of AKI, was tested by performing genome-wide association and linear regression in 429 patients of European descent using the outcome of peak serum creatinine while on vancomycin. We also tested the hypothesis that genetic variants associate with vancomycin pharmacokinetics, using vancomycin trough levels and calculated renal elimination rate constant as outcomes.
Link
Trefwoorden
Versies (1)
- 02-04-24 02-04-24 - Madita Rudolph
Houder van rechten
Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA
Geüploaded op
2 april 2024
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000894 Genome Wide Study of Vancomycin
Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
Similar models
Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
C0441833 (UMLS CUI [1,2])